Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients

ClinicalTrials.gov ID: NCT06657859

Public ClinicalTrials.gov record NCT06657859. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 7, 2026, 8:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Open-Label Extension Study to Assess the Safety and Efficacy of GLM101 Administered Intravenously to Participants With PMM2-CDG

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The goal of this clinical trial is to provide continued access to GLM101 to treat PMM2-CDG in people who have previously received GLM101 in other trials and learn about the long term effect of GLM101. Participants will complete weekly infusions of GLM101 at the same dose level received in previous trials.

Study identification

NCT ID: NCT06657859
Recruitment status: Enrolling by invitation
Study type: Interventional
Phase: Phase 2
Lead sponsor: Glycomine, Inc.; Industry
Enrollment: 90 participants

Conditions and interventions

Conditions

Interventions

GLM101 Drug

Drug

Eligibility (public fields only)

Age range: 2 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 29, 2024
Primary completion: Aug 31, 2029
Completion: Sep 30, 2029
Last update posted: Aug 18, 2026

2024 – 2029

United States locations

U.S. sites: 4
U.S. states: 4
U.S. cities: 4

Facility	City	State	ZIP	Site status
University of Minnesota	Minneapolis	Minnesota	55455	—
The Icahn School of Medicine at Mount Sinai	New York	New York	10029	—
The Children's Hospital of Philadelphia (CHOP)	Philadelphia	Pennsylvania	19104	—
Seattle Children's Hospital	Seattle	Washington	98105	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06657859, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 18, 2026 · Synced Sep 7, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06657859 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →